(Q35183830)

7 August 2017

1 reference

title

Pharmacology of airway inflammation in asthma and COPD. (English)

1 reference

chronic obstructive pulmonary disease

7 August 2017

main subject

1 reference

1 reference

1 reference

2

Ian Adcock

1 reference

7 August 2017

Gaetano Caramori

1

1 reference

7 August 2017

language of work or name

1 reference

1 January 2003

1 reference

Pulmonary Pharmacology & Therapeutics

7 August 2017

published in

1 reference

7 August 2017

volume

16

1 reference

7 August 2017

issue

5

1 reference

7 August 2017

page(s)

247-277

1 reference

Chronic obstructive pulmonary disease

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Inhaled glucocorticoids for asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Cellular and structural bases of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Distribution of therapeutic response in asthma control

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Corticosteroid reversibility in COPD is related to features of asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

High doses of inhaled corticosteroids in unstable chronic asthma. A multicenter, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

High dose inhaled budesonide in the treatment of severe steroid-dependent asthmatics. A two-year study

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Fluticasone propionate results in improved glucocorticoid receptor binding affinity and reduced oral glucocorticoid requirements in severe asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Airway inflammation, basement membrane thickening and bronchial hyperresponsiveness in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Corticosteroid-induced improvement in the PC20 of adenosine monophosphate is more closely associated with reduction in airway inflammation than improvement in the PC20 of methacholine

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

The effect of inhaled corticosteroids on the maximal degree of airway narrowing to methacholine in asthmatic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Time course of change in bronchial reactivity with an inhaled corticosteroid in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Reduction of budesonide after a year of increased use: a randomized controlled trial to evaluate whether improvements in airway responsiveness and clinical asthma are maintained

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Protective effects of fluticasone on allergen-induced airway responses and sputum inflammatory markers

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Low- and high-dose fluticasone propionate in asthma; effects during and after treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Significant variability in response to inhaled corticosteroids for persistent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Assessment and evaluation of symptomatic steroid-naive asthmatics without sputum eosinophilia and their response to inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Effects of treatment on airway inflammation and thickening of basement membrane reticular collagen in asthma. A quantitative light and electron microscopic study

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Inflammatory cells and eosinophilic activity in asthmatics investigated by bronchoalveolar lavage. The effects of antiasthmatic treatment with budesonide or terbutaline

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

A comparative study of the effects of an inhaled corticosteroid, budesonide, and a β2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: A randomized, double-blind, parallel-group controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Fiberoptic bronchoscopy and bronchial mucosal biopsies in asthmatics undergoing long-term high-dose budesonide aerosol treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Effect of inhaled steroids on airway hyperresponsiveness, sputum eosinophils, and exhaled nitric oxide levels in patients with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Effect of short-term treatment with low-dose inhaled fluticasone propionate on airway inflammation and remodeling in mild asthma: a placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Effect of low-dose beclomethasone dipropionate on asthma control and airway inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Relationship between exhaled nitric oxide and mucosal eosinophilic inflammation in children with difficult asthma, after treatment with oral prednisolone

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

A research method to induce and examine a mild exacerbation of asthma by withdrawal of inhaled corticosteroid

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Lung function and sputum characteristics of patients with severe asthma during an induced exacerbation by double-blind steroid withdrawal

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Review of the molecular and cellular mechanisms of action of glucocorticoids for use in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

The effects of glucocorticoids on human eosinophils

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Effect of inhaled corticosteroids on peripheral blood eosinophil counts and density profiles in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

The effects of inhaled budesonide on circulating eosinophil progenitors and their expression of cytokines after allergen challenge in subjects with atopic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

An inhaled corticosteroid, budesonide, reduces baseline but not allergen-induced increases in bone marrow inflammatory cell progenitors in asthmatic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

An overview of glucocorticoid anti-inflammatory actions

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

The pharmacologic control of mediator release from human basophils and mast cells

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Inhaled beclomethasone dipropionate downregulates CD4 and CD8 T-lymphocyte activation in peripheral blood of patients with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Inhaled beclomethasone dipropionate downregulates airway lymphocyte activation in atopic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Persistent airway T-lymphocyte activation in chronic corticosteroid-treated symptomatic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Prednisone-dependent asthma: inflammatory indices in induced sputum

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Effect of oral prednisone on airway inflammatory mediators in atopic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Corticosteroid inhibition of airway microvascular leakage

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Respiratory membrane permeability and bronchial hyperreactivity in patients with stable asthma. Effects of therapy with inhaled steroids

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Direct inhibitory action of glucocorticoid on glycoconjugate secretion from airway submucosal glands

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Vascularity in asthmatic airways: relation to inhaled steroid dose

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Effect of an inhaled glucocorticosteroid on airway mucosal blood flow in mild asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Evaluation of the antiinflammatory and phospholipase-inhibitory activity of calpactin II/lipocortin I.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Granulocyte/macrophage colony-stimulating factor stimulates the expression of the 5-lipoxygenase-activating protein (FLAP) in human neutrophils

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Dexamethasone Increases Expression of 5‐Lipoxygenase and its Activating Protein in Human Monocytes and THP‐1 Cells

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Effects of dexamethasone on mediator release from human lung fragments and purified human lung mast cells

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Arachidonic acid metabolism in normal human alveolar macrophages: stimulus specificity for mediator release and phospholipid metabolism, and pharmacologic modulation in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Macrophage-specific eicosanoid synthesis inhibition and lipocortin-1 induction by glucocorticoids

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Inhibition of eicosanoid biosynthesis by glucocorticoids in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Enhancement of leukotriene A4 biosynthesis in neutrophils from patients with rheumatoid arthritis after a single glucocorticoid dose.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Effects of glucocorticoids on endogenous and transcellular metabolism of eicosanoids in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

A novel pharmacologic action of glucocorticosteroids on leukotriene C4 catabolism

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Dexamethasone-induced increase in platelet-derived growth factor (B) mRNA in human alveolar macrophages and myelomonocytic HL60 macrophage-like cells

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Inhaled glucocorticoids decrease nitric oxide in exhaled air of asthmatic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

1 reference

7 January 2021

Prednisolone treatment in asthma. Reduction in the numbers of eosinophils, T cells, tryptase-only positive mast cells, and modulation of IL-4, IL-5, and interferon-gamma cytokine gene expression within the bronchial mucosa

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Inhaled corticosteroids increase interleukin-10 but reduce macrophage inflammatory protein-1alpha, granulocyte-macrophage colony-stimulating factor, and interferon-gamma release from alveolar macrophages in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Inhaled budesonide decreases airway inflammatory response to allergen.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Effect of inhaled glucocorticoids on IL-1 beta and IL-1 receptor antagonist (IL-1 ra) expression in asthmatic bronchial epithelium

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Malnutrition in chronic obstructive pulmonary disease: adding insult to injury

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Effects of inhaled glucocorticoids on bone density in premenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Inhaled corticosteroids are not beneficial in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Additive effects of salmeterol and fluticasone or theophylline in COPD

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Effect of High Dose Inhaled Steroid on Cells, Cytokines, and Proteases in Induced Sputum in Chronic Obstructive Pulmonary Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Effects of fluticasone propionate on inflammatory cells in COPD: an ultrastructural examination of endobronchial biopsy tissue

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Redox-dependent regulation of nuclear import of the glucocorticoid receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Glucocorticoid receptor localization in normal and asthmatic lung

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Glucocorticoid Receptor beta: View II

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Glucocorticoid Receptor beta: View I

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Interaction of steroid hormone receptors with the transcription initiation complex

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

New twists in gene regulation by glucocorticoid receptor: is DNA binding dispensable?

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Molecular mechanisms of glucocorticosteroid actions.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Alternative mechanisms for long-acting beta(2)-adrenergic agonists in COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Salmeterol prevents aspirin-induced attacks of asthma and interferes with eicosanoid metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Effect of short- and long-acting inhaled beta2-agonists on exhaled nitric oxide in asthmatic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Asthma control during long-term treatment with regular inhaled salbutamol and salmeterol.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Effects of salmeterol on mucosal inflammation in asthma: a placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Clinical outcome of adding long-acting beta-agonists to inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Long-acting inhaled beta(2)-agonist therapy in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA).

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Long-acting beta-agonist treatment in patients with persistent asthma already receiving inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

An overview of nine clinical trials of salmeterol in an asthmatic population

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

The efficacy and safety of salmeterol compared to theophylline: meta-analysis of nine controlled studies

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Evaluation of different inhaled combination therapies (EDICT): a randomised, double-blind comparison of Seretide (50/250 microg bd Diskus vs. formoterol (12 microg bd) and budesonide (800 microg bd) given concurrently (both via Turbuhaler) in patien

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Inhaled salmeterol/fluticasone propionate combination: a review of its use in persistent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Inhaled budesonide/formoterol combination

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Compliance with inhaled glucocorticoids and concomitant use of long-acting beta2-agonists

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Can oral beta2 agonists cause heart failure?

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Cardiac risks with beta agonists

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Risk of non-fatal cardiac failure and ischaemic heart disease with long acting beta 2 agonists

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

A comparison of two long-acting beta-agonists, oral bambuterol and inhaled salmeterol, in the treatment of moderate to severe asthmatic patients with nocturnal symptoms. The French Bambuterol Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Effect of long-term salmeterol treatment on exercise-induced asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta2 agonists

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

A high dose of albuterol does not overcome bronchoprotective subsensitivity in asthmatic subjects receiving regular salmeterol or formoterol

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

An inhaled glucocorticoid does not prevent tolerance to the bronchoprotective effect of a long-acting inhaled beta 2-agonist

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Functional antagonism with formoterol and salmeterol in asthmatic patients expressing the homozygous glycine-16 beta(2)-adrenoceptor polymorphism

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Effects of theophylline on tolerance to the bronchoprotective actions of salmeterol in asthmatics in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

An antiinflammatory effect of salmeterol, a long-acting beta(2) agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

The effects of regular inhaled formoterol, budesonide, and placebo on mucosal inflammation and clinical indices in mild asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Effects of budesonide and formoterol on NF-kappaB, adhesion molecules, and cytokines in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Effects of once-daily formoterol and budesonide given alone or in combination on surrogate inflammatory markers in asthmatic adults

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Effect of salmeterol on allergen-induced airway inflammation in mild allergic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Effect of eight weeks of treatment with salmeterol on bronchoalveolar lavage inflammatory indices in asthmatics

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Early changes in T lymphocytes recovered by bronchoalveolar lavage after local allergen challenge of asthmatic airways

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

A long-term study of the antiinflammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

The effect of salmeterol on nocturnal symptoms, airway function, and inflammation in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Potential masking effects of salmeterol on airway inflammation in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Effectiveness of salmeterol versus ipratropium bromide on exertional dyspnoea in COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Inhaled salmeterol: a review of its efficacy in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium : a 3-week, randomized, double-blind, within-patient, multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Interactions between corticosteroids and beta-adrenergic agonists in asthma disease induction, progression, and exacerbation

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Comparison of the Relative Efficacy of Formoterol and Salmeterol in Asthmatic Patients

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Beta-adrenergic receptors and their regulation

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Regulation of camp-inducible genes by creb

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Switching of the coupling of the beta2-adrenergic receptor to different G proteins by protein kinase A.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

beta-Adrenergic activation of p38 MAP kinase in adipocytes: cAMP induction of the uncoupling protein 1 (UCP1) gene requires p38 MAP kinase

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Differential down-regulation of pulmonary beta 1- and beta 2-adrenoceptor messenger RNA with prolonged in vivo infusion of isoprenaline

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Regulation of TNF-alpha-induced eotaxin release from cultured human airway smooth muscle cells by beta2-agonists and corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Synergistic inhibition by beta(2)-agonists and corticosteroids on tumor necrosis factor-alpha-induced interleukin-8 release from cultured human airway smooth-muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Effects of formoterol and budesonide on GM-CSF and IL-8 secretion by triggered human bronchial epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Ligand-independent activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Comparison of addition of theophylline to inhaled steroid with doubling of the dose of inhaled steroid in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Inhaled corticosteroids reduce the severity of bronchial hyperresponsiveness in asthma but oral theophylline does not.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Anti-inflammatory effects of low-dose oral theophylline in atopic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Theophylline--an immunomodulatory role in asthma?

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Low-dose theophylline reduces eosinophilic inflammation but not exhaled nitric oxide in mild asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Theophylline: potential antiinflammatory effects in nocturnal asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Effects of theophylline on inflammatory cells and cytokines in asthmatic subjects: a placebo-controlled parallel group study

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Effect of theophylline and adenosine on eosinophil function

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Theophylline suppresses the release of tumour necrosis factor-alpha by blood monocytes and alveolar macrophages.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

The effect of theophyllamine on T-lymphocyte activation in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Theophylline and the immune response: in vitro and in vivo effects

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Theophylline induced non specific suppressor activity in human peripheral blood lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Theophylline: new perspectives for an old drug

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Immunomodulation by theophylline in asthma. Demonstration by withdrawal of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Effects of theophylline withdrawal in severe chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Effect of theophylline on induced sputum inflammatory indices and neutrophil chemotaxis in chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Salmeterol plus theophylline combination therapy in the treatment of COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1beta-induced histone H4 acetylation on lysines 8 and 12.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression, and inhibits glucocorticoid actions in alveolar macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Effect of a leukotriene B4 receptor antagonist, LY293111, on allergen induced responses in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

The role of leukotrienes in upper and lower airway inflammation and the implications for treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Treatment of asthma with drugs modifying the leukotriene pathway.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Leukotriene antagonists and synthesis inhibitors: new directions in asthma therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Effects of LTD4 on human airway smooth muscle cell proliferation, matrix expression, and contraction In vitro: differential sensitivity to cysteinyl leukotriene receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Leukotrienes as Mediators of Airway Obstruction

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Bronchoprotective effects of leukotriene receptor antagonists in asthma: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

New approaches to anti-inflammatory therapy for asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Comparative efficacy and anti-inflammatory profile of once-daily therapy with leukotriene antagonist or low-dose inhaled corticosteroid in patients with mild persistent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomised double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction. A randomized, double-blind trial. Exercise Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Comparative effects of long-acting beta2-agonists, leukotriene receptor antagonists, and a 5-lipoxygenase inhibitor on exercise-induced asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction. Montelukast/Salmeterol Exercise Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Effect of a leukotriene antagonist, ONO-1078, on bronchial hyperresponsiveness in patients with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

The effect of montelukast (MK-0476), a cysteinyl leukotriene receptor antagonist, on allergen-induced airway responses and sputum cell counts in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Anti-inflammatory and lung function effects of montelukast in asthmatic volunteers exposed to sulfur dioxide

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Effects of pranlukast on chemical mediators in induced sputum on provocation tests in atopic and aspirin-intolerant asthmatic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Reduction of eosinophilic inflammation in the airways of patients with asthma using montelukast

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Effect of the leukotriene receptor antagonist pranlukast on cellular infiltration in the bronchial mucosa of patients with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. Zileuton Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

A controlled trial of the effect of the 5-lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

1 reference

7 January 2021

Pharmacokinetics and pharmacodynamics of the leukotriene B4 receptor antagonist CP-105,696 in man following single oral administration

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Comparison of the bronchodilating effect of salmeterol and zafirlukast in combination with that of their use as single treatments in asthma and chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Anti-inflammatory drugs: new multitarget compounds to face an old problem. The dual inhibition concept.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Genetic Determinants of 5–Lipoxygenase Transcription

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Mutations in the human 5-lipoxygenase gene

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Egr-1 and Sp1 interact functionally with the 5-lipoxygenase promoter and its naturally occurring mutants

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Leukotriene C4 synthase polymorphism and aspirin-induced asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Enhanced expression of the leukotriene C(4) synthase due to overactive transcription of an allelic variant associated with aspirin-intolerant asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

5' flanking region polymorphism of the gene encoding leukotriene C4 synthase does not correlate with the aspirin-intolerant asthma phenotype in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Characterization of the human cysteinyl leukotriene 2 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Effects of sodium cromoglycate and nedocromil sodium on histamine secretion from human lung mast cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Pharmacology of sodium cromoglycate

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Cromolyn sodium suppresses eosinophilic inflammation in patients with aspirin-intolerant asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Potent block of Cl- channels by antiallergic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Inhaled disodium cromoglycate (DSCG) as maintenance therapy in children with asthma: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Long-term effects of budesonide or nedocromil in children with asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Inhaled transmembrane ion transport modulators and non-steroidal anti-inflammatory drugs in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Furosemide: progress in understanding its diuretic, anti-inflammatory, and bronchodilating mechanism of action, and use in the treatment of respiratory tract diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Inhaled frusemide is highly effective in preventing ultrasonically nebulised water bronchoconstriction

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Effect of inhaled frusemide and oral indomethacin on the airway response to hypertonic saline challenge in asthmatic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Potentiation of the antireactive, antiasthmatic effect of inhaled furosemide by inhaled lysine acetylsalicylate

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Immunosuppressive and cytotoxic effects of furosemide on human peripheral blood mononuclear cells

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Serology of chlamydia in relation to asthma and bronchial hyperresponsiveness

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Asthma, atopy and Chlamydia pneumoniae antibodies in adults

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Chlamydia pneumoniae serological status is not associated with asthma in children or young adults

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Lack of correlation between Chlamydia pneumoniae antibody titers and adult-onset asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Detection of Mycoplasma pneumoniae in the airways of adults with chronic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Association of Mycoplasma pneumoniae antigen with initial onset of bronchial asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Mycoplasma pneuminia infection. A follow-up study of 50 children with respiratory illness

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Mycoplasma pneumoniae: acute illness, antibiotics, and subsequent pulmonary function

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Interplay between mycoplasma surface proteins, airway cells, and the protean manifestations of mycoplasma-mediated human infections

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Immunoelectron microscopic studies reveal differences in distribution of sialo-oligosaccharide receptors for Mycoplasma pneumoniae on the epithelium of human and hamster bronchi

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Dexamethasone and oxytetracycline reverse the potentiation of neurogenic inflammation in airways of rats with Mycoplasma pulmonis infection

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Substance P and its receptor neurokinin 1 expression in asthmatic airways

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Evaluation of blood vessels and edema in the airways of asthma patients: regulation with clarithromycin treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Chlamydia pneumoniae, Strain TWAR, Infection in Patients with Chronic Obstructive Pulmonary Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Diagnosis of Chlamydia pneumoniae infection in patients with chronic obstructive pulmonary disease by micro-immunofluorescence and ELISA.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Chlamydia pneumoniae infection in patients with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Increased frequency of Chlamydia pneumoniae antibodies in patients with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Prevalence of Chlamydia pneumoniae specific antibodies in different clinical situations and healthy subjects in Izmir, Turkey

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

The role of chlamydia in the pathogenesis of pulmonary emphysema. Electron microscopy and immunofluorescence reveal corresponding findings as in atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Immunohistochemical staining for Chlamydia pneumoniae is increased in lung tissue from subjects with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Failure to detect the presence of Chlamydia pneumoniae in sarcoid pathology specimens

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Chlamydia pneumoniae serology, lung function decline, and treatment for respiratory disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Low-dose methotrexate treatment in severe glucocorticoid-dependent asthma: effect on mucosal inflammation and in vitro sensitivity to glucocorticoids of mitogen-induced T-cell proliferation

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Trial of cyclosporin in corticosteroid-dependent chronic severe asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Double-blind, placebo-controlled study of cyclosporin A as a corticosteroid-sparing agent in corticosteroid-dependent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Treatment of steroid-dependent bronchial asthma with cyclosporin

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Attenuation of the allergen-induced late asthmatic reaction by cyclosporin A is associated with inhibition of bronchial eosinophils, interleukin-5, granulocyte macrophage colony-stimulating factor, and eotaxin

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Effect of cyclosporin A on the allergen-induced late asthmatic reaction

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

IL-5 production by CD4+ T cells of asthmatic patients is suppressed by glucocorticoids and the immunosuppressants FK506 and cyclosporin A.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Regulation of interleukin-5 production by peripheral blood mononuclear cells from atopic patients with FK506, cyclosporin A and glucocorticoid

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Control of IL-5 production by human helper T cells as a treatment for eosinophilic inflammation: comparison of in vitro and in vivo effects between selective and nonselective cytokine synthesis inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

The immunomodulatory drugs cyclosporin A, mycophenolate mofetil, and sirolimus (rapamycin) inhibit allergen-induced proliferation and IL-5 production by PBMCs from atopic asthmatic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Can clinical response to cyclosporin in chronic severe asthma be predicted by an in vitro T-lymphocyte proliferation assay?

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Glucocorticoid resistant asthma: T-lymphocyte steroid metabolism and sensitivity to glucocorticoids and immunosuppressive agents

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

The effect of dexamethasone, cyclosporine, and rapamycin on T-lymphocyte proliferation in vitro: comparison of cells from patients with glucocorticoid-sensitive and glucocorticoid-resistant chronic asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Omalizumab, a novel anti-IgE therapy in allergic disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Effect of anti-IgE therapy in patients with peanut allergy

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Therapeutic strategies for allergic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Glucocorticoids: new mechanisms and future agents

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Species-specific differences in the glucocorticoid receptor transactivation function upon binding with betamethasone-esters

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Effect of inhaled ciclesonide on airway responsiveness to inhaled AMP, the composition of induced sputum and exhaled nitric oxide in patients with mild asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Recent advances in retrometabolic design approaches

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Asthma therapy in the new millennium

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Systemic effect comparisons of six inhaled corticosteroid preparations

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

New treatments for COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Recent advances in PDE4 inhibitors as immunoregulators and anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

4D or not 4D - the emetogenic basis of PDE4 inhibitors uncovered?

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Selective phosphodiesterase inhibitors for the treatment of asthma and chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Second-generation antihistamines: a comparative review

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Role of histamine in the pathophysiology of asthma: immunomodulatory and anti-inflammatory activities of H1-receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Role of mediators in late-phase allergic symptoms including congestion

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Chemokine receptors in airway disease: which receptors to target?

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Chemokine receptors in inflammation: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Cytokines and chemoattractants in allergic inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

CCR8 is not essential for the development of inflammation in a mouse model of allergic airway disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

CCR3 antagonists: a potential new therapy for the treatment of asthma. Discovery and structure-activity relationships

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Differences in Airway Inflammation in Patients with Fixed Airflow Obstruction Due to Asthma or Chronic Obstructive Pulmonary Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Decreased T lymphocyte infiltration in bronchial biopsies of subjects with severe chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

The C-C chemokine receptors CCR4 and CCR8 identify airway T cells of allergen-challenged atopic asthmatics

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Increased expression of the chemokine receptor CXCR3 and its ligand CXCL10 in peripheral airways of smokers with chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

A non-peptide CCR5 antagonist inhibits collagen-induced arthritis by modulating T cell migration without affecting anti-collagen T cell responses

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Cytokines and therapy in COPD: a promising combination?

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Changes in bronchial inflammation during acute exacerbations of chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Bacterial infection and the pathogenesis of COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Adapting pharmacokinetic properties of a humanized anti-interleukin-8 antibody for therapeutic applications using site-specific pegylation

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Increased levels of the chemokines GROalpha and MCP-1 in sputum samples from patients with COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

The Selective CXCR2 Antagonist SB272844 Blocks Interleukin-8 and Growth-related Oncogene-α-mediated Inhibition of Spontaneous Neutrophil Apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Mechanisms in COPD: differences from asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Expression of GATA family of transcription factors in T-cells, monocytes and bronchial biopsies

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Cross-talk between pro-inflammatory transcription factors and glucocorticoids.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Activation and localization of transcription factor, nuclear factor-kappaB, in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Treatment of allergic airway inflammation and hyperresponsiveness by antisense-induced local blockade of GATA-3 expression

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Oxidative Stress in Chronic Obstructive Pulmonary Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Interleukin-4 and interleukin-5 gene expression and inflammation in the mucus-secreting glands and subepithelial tissue of smokers with chronic bronchitis. Lack of relationship with CD8(+) cells

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Interleukin-4, -5, and -6 and tumor necrosis factor-alpha in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Cytokine modulators as novel therapies for asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

What's in the pipeline? Prospects for monoclonal antibodies (mAbs) as therapies for lung diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Efficacy of soluble IL-4 receptor for the treatment of adults with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Th2 cytokines and asthma. The role of interleukin-5 in allergic eosinophilic disease

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Anti-interleukin-9 antibody treatment inhibits airway inflammation and hyperreactivity in mouse asthma model.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Balance of matrix metalloprotease-9 and tissue inhibitor of metalloprotease-1 from alveolar macrophages in cigarette smokers. Regulation by interleukin-10

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Attenuated production of intracellular IL-10 and IL-12 in monocytes from patients with severe asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Haplotype associated with low interleukin-10 production in patients with severe asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

A defect in corticosteroid-induced IL-10 production in T lymphocytes from corticosteroid-resistant asthmatic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

New treatments for chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Regulation of helper T cell differentiation and recruitment in airway inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Interleukin-12: potential role in asthma therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

The effects of nebulized recombinant interferon-gamma in asthmatic airways

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

The kinetics of change in cytokine production by CD4 T cells during conventional allergen immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Treatment with IFN-alpha in corticosteroid-unresponsive asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Suppression of airway eosinophilia by killed Mycobacterium vaccae-induced allergen-specific regulatory T-cells

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Drugs for the treatment of allergic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Effect of suplatast tosilate, a Th2 cytokine inhibitor, on steroid-dependent asthma: a double-blind randomised study. Tokyo Joshi-Idai Asthma Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Effects of suplatast tosilate (IPD Capsules) on the production of active oxygen by neutrophils and of IL-8 by mononuclear cells

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

DNA-based immunotherapeutics for the treatment of allergic disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Immunostimulatory sequence oligodeoxynucleotide-based vaccination and immunomodulation: two unique but complementary strategies for the treatment of allergic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Modulation of murine allergic rhinosinusitis by CpG oligodeoxynucleotides.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Airway inflammation and tachykinins: prospects for the development of tachykinin receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

Airway hypersecretion in allergic rhinitis and asthma: new pharmacotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900070-1

7 January 2021

10.1016/S1094-5539(03)00070-1

Identifiers

DOI

1 reference

7 August 2017

1 reference